TSN 222
Alternative Names: TSN-222Latest Information Update: 10 Jun 2025
At a glance
- Originator Tyligand Bioscience
- Class Antineoplastics; Small molecules
- Mechanism of Action Protein tyrosine phosphatase modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Lymphoma; Malignant melanoma; Solid tumours
Most Recent Events
- 25 Apr 2025 Efficacy and adverse event data from phase I/II in Solid tumors and Lymphoma presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Pharmacodynamics data from preclinical trial in Solid tumors presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 26 Jul 2023 Phase-I/II clinical trials in Malignant melanoma (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (Intratumoural) (NCT05842785)